|Over a month ago|
In8bio initiated with a Buy at Mizuho » 08:5308/2408/24/21
Mizuho analyst Mara…
Mizuho analyst Mara Goldstein initiated coverage of In8bio with a Buy rating and $12 price target.
In8bio initiated with a Buy on cancer potential at B. Riley » 08:1008/2308/23/21
B. Riley analyst Kalpit…
B. Riley analyst Kalpit Patel initiated coverage of In8bio with a Buy rating and $19 price target. IN8bio is clinical-stage biotech company focused exclusively on advancing gamma-delta T cells as a potential option for difficult-to-treat cancers, Patel tells investors in a research note. The analyst believes gamma-delta T cells are likely the ideal source of cells for attacking solid tumors and that the company's management has implemented a rational strategy to tackle glioblastoma multiforme.
In8bio initiated with a Buy at B. Riley » 05:1008/2308/23/21
B. Riley initiated…
B. Riley initiated coverage of In8bio with a Buy rating and $19 price target.
Opening Day: Sportradar files for IPO after SPAC talks break off » 08:2708/2108/21/21
ARBK, ARBKF, PRCT, SRAD, QNIU, CMSL, SPRK, SCAN, AUTH, BLK, SPG, MS, GS, BCS, BAC, MXCT, RXST, TNYA, RANI, NUVL, ICVX, RSKD, OMGA, IMRX, INAB, HOOD, RLYB, ABVC
In a quiet week for IPOs,…
In8bio completes dosing of first cohort in Phase 2 trial with Allogeneic » 08:1808/1108/11/21
IN8bio announced completion of dosing of the first patient cohort in a Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant. The three patients comprising the first cohort did not experience any severe adverse infusion reactions or dose limiting toxicities to date. The first two patients are at 14.5 months and 12.2 months, respectively, post-HSCT as of June 30, 2021, and continue to be in complete remission. "For patients with high-risk leukemia, the availability of HSCT is a path toward a potential cure, but rates of leukemic relapse remain high," said William Ho, Chief Executive Officer and co-founder of IN8bio. "Research by our Chief Scientific Officer, Dr. Lamb, and others has shown that that high numbers of circulating gamma-delta T cells have been correlated with improved survival outcomes in these patients. Our goal with INB-100 is to generate an anti-leukemic effect by supplementing patients' immune systems with allogeneic gamma-delta T cells to reduce relapse and improve overall survival in patients who have undergone an allogeneic HSCT. Although early, we are encouraged by data obtained to date indicating the potential for well-tolerated allogeneic gamma delta T-cell therapies. We look forward to announcing additional data on this program in 2022."
In8bio appoints Fairbairn and Greenwood to board of directors » 08:2308/0408/04/21
IN8bio announces the…
IN8bio announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors. Fairbairn is currently a principal of Transcend Partners and was co-founder and CEO of Ascend Capital for nearly 20 years. Greenwood serves as Managing Partner of Binney Street Capital and co-founded and is currently CEO of LUCA Biologics. Fairbairn will be serving on the nomination and corporate governance committee, while Greenwood will be serving on the audit and compensation committees. Their terms will both expire at the annual meeting of stockholders to be held in 2022.
Opening Day: Robinhood shares fall after IPO » 08:5307/3107/31/21
MXCT, RXST, TNYA, RANI, OMGA, IMRX, INAB, DOLE, HOOD, NUVL, ICVX, RSKD, COOK, RLYB, DUOL, MLNK, PWSC, CADL, SNTG, RNAZ, AGRI, MITQ, IINN, UNCY, SPRK, QNIU, CMSL, SCAN, AUTH, MS, GS, BCS, BAC, BLK, SPG
Shares of Robinhood…
In8bio opens at $10, IPO priced at $10 » 11:3707/3007/30/21
In8bio (INAB) priced 4M…
In8bio (INAB) priced 4M shares at $10.00. The deal range was $10.00-$12.00. B. Riley acted as sole book running manager for the offering. In8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies utilizing its DeltEx platform.
In8bio 4M share IPO priced at $10.00 » 07:0507/3007/30/21
The deal range was…
The deal range was $10.00-$12.00. B. Riley acted as sole book running manager for the offering.